Interestingly, YAP’s expression and tumoral effects run in parallel to those of WIP: YAP is markedly downregulated in hematological malignancies, including lymphomas, leukemias and multiple myeloma, and is upregulated in cell lines from solid tumors of epithelial origin (Cottini et al., 2014). Here, WIPF1 is linked to lymphoma.